National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main
Page Options
Print This Page
E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

      
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Maintenance Rituximab for Follicular Lymphoma

Azacitidine Improves Survival in MDS

Second Stem Cell Transplant Not Helpful in Myeloma
Related Pages
Coping with Cancer
Managing side effects and complications caused by cancer and its treatment.

Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.
Supportive Care Trial Results
21.  Added to Standard Antinausea Medicines, Aprepitant Improves Results
(Posted: 10/28/2003, Reviewed: 05/06/2005) - Drugs used to treat nausea and vomiting are called antiemetics. Two studies examined a new antiemetic drug called aprepitant (brand name EMEND®) in patients undergoing cancer treatment. In both studies, patients who received aprepitant suffered less nausea and vomiting than patients who received standard antiemetic drugs. The studies were from the Journal of Clinical Oncology, published online Oct. 14, 2003; in print issue Nov. 15, 2003.

22.  Implantable Device May Offer Better Pain Management
(Posted: 10/23/2002, Reviewed: 03/23/2005) - Patients with advanced cancer who used an implantable drug-delivery device to control their pain had better pain relief, fewer toxic side effects, and better survival than patients who received intensive medical pain management, researchers reported in the October 1, 2002, issue of the Journal of Clinical Oncology.

23.  Stress Management Training for Cancer Patients
(Posted: 08/07/2002, Reviewed: 03/23/2005) - A self-administered stress management training program did a better job of helping patients cope with the adverse effects of chemotherapy than a one-hour program in which training was given by mental health professionals, according to the June 15, 2002, Journal of Clinical Oncology.

24.  Zoledronic Acid Reduces Bone Complications of Advanced Prostate Cancer
(Posted: 06/21/2002, Reviewed: 03/09/2005) - In a study published in the October 2, 2002, issue of the Journal of the National Cancer Institute, patients with prostate cancer that had spread to the bones had fewer fractures and other bone complications when they took a new drug, zoledronic acid (also called zolendronate or Zometa®) than when they took a placebo.

25.  For Transplant Patients, Oral Antinausea Drug May Be Cheaper, Just as Effective
(Posted: 03/14/2002, Reviewed: 03/23/2005) - For patients receiving high-dose chemotherapy or radiation to prepare them for a bone marrow transplant (BMT), intravenous antiemetics have seemed better than oral agents at controlling nausea and vomiting. Now the results of a November 2001 study challenge this assumption.
< Previous  2 3 4 5 6   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov